Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by mercedesmanon Nov 13, 2021 2:32pm
196 Views
Post# 34123495

RE:RE:RE:RE:RE:Seto said we'd hit 90 patients by Q4

RE:RE:RE:RE:RE:Seto said we'd hit 90 patients by Q4

Accountprince wrote: If Nasdaq was the end game they would have done it already.  They did the things to get ready (accounting consistency, SH permission etc) a while back and the markets couldn't have been more ideal the last two years.  Tech and healthcare the sexiest of the bunch.  They would have also finished the wide dispersion of new issues a while back.  Those rock bottom share issues would look bad if they were planning to go public on Nasdaq.  Walden would have been busy.    Lastly, they look too pathetic as management and Bored to garner any attention - not the least of which is a recent record of doing virtually nothing.  So its a smokescreen.

A buyout of all or each of the two segments will happen.  If separate deals Dialco will be sold first and then PMX.  What are your thoughts MM? 


More and more I'm coming around to that way of thinking although I still haven't completely ruled out a spin- off IPO, or a Nasdaq endgame. But as you say, it doesn't fit with the current unfolding of events and with what should have been a golden opportunity ( ie perfect market to create value) 

there is more to the apparent bungling and key-stone cops routine than meets the eye IMO ( including the IR and BB side comedy scetches ) 

Covid was both a real issue and good cover for awhile ... now they need a new narrative to buy time. 

I see increasing odds of a single buyer vs two separate buyers. 


MM
 

<< Previous
Bullboard Posts
Next >>